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Despite the widespread use of antidepressant medications that block serotonin 
(5 hydroxytryptamine; 5-HT) and/or norepinephrine (NE) transporters, such as SSRIs (selective 
serotonin reuptake inhibitors) or SNRIs (serotonin and norepinephrine reuptake inhibitors) 
(Fig. 1), the underlying neurobiological basis of action of these agents is poorly understood. 
Increases in serotonergic function are hypothesized to have beneficial effects on depressive 
symptoms. However, which of the 14 different neuronal receptors sensitive to 5-HT accounts for 
the therapeutic effects of SSRIs and SNRIs remains undetermined. The development of drugs 
that activate or block specific 5-HT receptors may help to circumvent the two main limitations of 
current antidepressants: low efficacy and delayed onset of therapeutic action. What follows is a 
short summary of the author’s views on this matter. 
 Major depression is a severe psychiatric syndrome with a lifetime prevalence of 10% 
and 20% for men and women, respectively, and high socioeconomic impact [1]. Unfortunately, 
the increasing cost of depression and related affective disorders has not been paralleled by 
improvements in the efficacy of antidepressant treatment. SSRIs and SNRIs are 
pharmacological refinements of the first generation of antidepressant drugs – tricyclic drugs 
such as imipramine or chlorimipramine – discovered serendipitously while searching for new 
antipsychotic drugs with a chemical structure similar to that of chlorpromazine (Fig. 1). In 
addition to blocking monoamine reuptake, tricyclic antidepressants exhibit high affinity for a 
number of neurotransmitter receptors (α1-adrenoceptors, histamine H1, muscarininc receptors, 
etc.). The interaction of tricyclic drugs with these receptors is responsible for their adverse side 
effects (postural hypotension, dry mouth, blurred vision, constipation, memory or cognitive 
impairment, etc.), which force many patients to abandon treatment with these drugs. The 
synthesis of new molecules inhibiting monoamine reuptake, devoid of these additional 
pharmacological activities, fostered the development of a new era in the treatment of major 
depression and other psychiatric diseases. The SSRIs – and later, the SNRIs – allowed patients 
to comply with therapeutic regimes, thereby increasing the overall numbers of patients 
experiencing antidepressant effects.  
 However, despite increased compliance, the efficacy of SSRIs did not surpass that of 
some tricyclic drugs, such as clomipramine [2,3]. Clinical trials with selected patient populations 
typically indicated response and remission rates of 60% and 40%, respectively, with SSRIs 
[4,5]. However, naturalistic studies, such as the STAR*D (Sequenced Treatment Alternatives to 
Relieve Depression) trial revealed a less promising situation, with response and remission rates 
of ~50% and a ~30%, respectively, after treatment with the SSRI S-citalopram (Fig. 1). 
Augmentation strategies with drugs not targeting the serotonin transporter (SERT) in patients 
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not responding to SSRIs yielded similar remission rates, around 30% [6]. Thus, these “real 
world” figures indicate that a very large percentage of patients treated with SSRIs show partial 
responses, leaving much room for improvement in antidepressant treatment.  
 The last two decades have witnessed major advances in our knowledge of glutamatergic 
transmission. In addition to direct excitatory activity mediated by ionotropic receptors (AMPA, 
NMDA, KA), glutamate can exert modulatory actions, similar to those of monoamines, via the 
activation of three families of metabotropic receptors, with a total of 8 different receptors 
identified (mGluR1-mGluR8), which offer potentially new avenues for neuropsychiatric drug 
development. For example, an mGluR2/3 agonist is being developed for the treatment of 
schizophrenia [7]. This is the first antipsychotic drug devoid of affinity for dopamine receptors 
illustrating the potential of mGluRs in drug development.  Moreover, the non-competitive NMDA 
antagonist ketamine can evoke rapid (~2 h) and persistent (up to 1 wk) antidepressant effects 
after a single dose in treatment-resistant depressed patients [8]. Interestingly, the dose used in 
antidepressant clinical trials of ketamine is the same as that displaying psychotomimetic effects. 
Overall, this suggests that the glutamatergic system may offer excellent opportunities for the 
development of antidepressant drugs overcoming the limitations of SSRIs and SNRIs. Yet, 
despite these promising results, the development of glutamatergic antidepressants may be 
hampered or delayed for several reasons, described briefly below. 
 With the exception of the basal ganglia – where GABA is the principle neurotransmitter – 
the basic wiring of the brain comprises excitatory glutamatergic neurons. This raises the 
possibility that glutamatergic drugs will elicit new and unexpected side effects, different from 
those of SSRIs or SNRIs, given the distinct roles played by glutamate and the monoamines in 
brain function. In addition to efficacy, the safety of new glutamatergic drugs will be a major issue 
that will require testing in large numbers of patients for long periods of time in phase IV clinical 
trials. Further, at the time of writing, CNS drug development is being abandoned or reduced by 
several large pharmaceutical companies, thus reducing overall research and development 
aimed identifying new targets and novel therapeutics. Thus, it is likely that antidepressant drug 
development in upcoming years will not broaden beyond monoaminergic systems. 
Monoaminergic drugs offer advantages associated with >50 years of clinical experience, with 
millions of patients treated, and a relatively good knowledge of their side effects.  
 As stated above, a major problem of SSRIs and SNRIs is their poor efficacy and slow 
clinical action. With an almost saturated antidepressant market, new drugs should be faster 
and/or more efficacious than SSRIs and SNRIs to achieve success. These new developments 
must be based on the knowledge of the role played by the different 5-HT receptors in 
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depression, a highly complex field, given the existence of 14 different 5-HT receptors, different 
localizations in brain networks, and sometimes opposing actions on neuronal activity after 
stimulation by 5-HT. Presynaptic 5-HT1A and 5-HT1B autoreceptors are suspected of playing a 
major detrimental role in current antidepressant therapy due to activation of negative feedback 
mechanisms operating in 5-HT neurons [9, 10]. Conversely, activation of postsynaptic 5-HT1A 
receptors in corticolimbic networks has positive antidepressant action [11,12]. This paradoxical 
situation may perhaps be solved by small-interferring RNA (siRNA) mechanisms selectively 
targeting pre- or postsynaptic receptors [13] or by the development of agonists selective for 
postsynaptic 5-HT1A receptors [14,15]. On the other hand, blockade of 5-HT2A/2C receptors 
improves the actions of SSRIs, whereas 5-HT2B receptor activation enhances serotonergic 
activity and shows antidepressant-like activity in rodents [16]. 5-HT3 receptor blockade can also 
augment the antidepressant action of SERT inhibition, whereas 5-HT4 receptor activation has 
antidepressant effects on its own and augments SSRI effects [17]. Finally, blockade of 5-HT6 
and 5-HT7 receptors may also improve the antidepressant effects of SERT inhibition (very little 
is known about the role of 5-HT5 receptors) [18,19]. Given the poor capabilities to model 
depressive symptoms in animals, it is unclear whether these different serotonin receptor 
pharmacologies have selective actions on particular groups of symptoms (e.g., affective, 
cognitive, somatic, etc.) or affect a range of symptoms, similar to SSRIs and SNRIs.  
 These observations indicate that the activation of the various 5-HT receptors by SSRI 
and SNRI has opposing effects on the activity of brain networks underlying their therapeutic 
effects. Therefore, it would be advisable to design antidepressant drugs encompassing agonist 
and antagonist activities at most relevant 5-HT receptors, an objective likely unfeasible from a 
chemical point of view. On the other hand, it is uncertain whether the selective activation of a 
single 5-HT receptor subtype is able to elicit antidepressant effects superior to those of current 
drugs. Therefore, future antidepressant strategies might include combinations of SERT 
blockade plus some of the above activities, an approach initiated by recently developed 
antidepressant drugs (e.g., vilazodone or Lu AA21004, also known as vortioxetine; Fig. 1). In 
addition to blocking SERT, both drugs incorporate partial agonist activity at 5-HT1A receptors. 
Also, vortioxetine shows antagonist activity at 5-HT3, 5-HT1B, and 5-HT7 receptors. Both drugs 
elevate extracellular 5-HT to a great extent compared to SSRIs, possibly by overcoming 
negative feed-back mechanisms that limit the full effect of SERT blockade [20,21]. Future 
serotonergic drugs may also include other targets potentially useful for antidepressant activity, 
such as blockade of 5-HT2A/2C receptors or activation of 5-HT4 receptors. Likewise, further 
clarification of brain elements (neurotransmitters, receptors, cells, networks) responsible for the 
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therapeutic effects of antidepressant drugs will guide the development of new generations of 
antidepressants overcoming the important limitations of current drugs. 
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Figure legend 
 
Figure 1. Structures of psychoactive drugs. Chlorpromazine is an antipsychotic that served as the 
framework for the discoveries of imipramine and clomipramine, tricyclic monoamine reuptake 
inhibiting antidepressants having multiple off-target effects that limit usage. Based on the efficacy 
of the tricyclics, newer antidepressants have been developed that selectively inhibit serotonin 
reuptake (SSRIs; fluoxetine, paroxetine, S-citalopram) or are dual serotonin-norepinephrine 
uptake inhibitors (SNRIs; duloxetine, venlafaxine). New antidepressant drugs that inhibit 
serotonin reuptake and have added action as partial 5-HT1A agonists have recently been 
developed: vilazodone (EMD 68843) and vortioxetine (LuAA21004).  The latter drug shows 
additional affinity for other 5-HT receptors (see text).  
 
